These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 9016339)

  • 41. [Nicotinic currents of cultured rat superior cervical ganglion neurons and use-dependent block by mecamylamine].
    Liu QS; He XP; Liu CG
    Zhongguo Yao Li Xue Bao; 1995 Nov; 16(6):520-3. PubMed ID: 8732047
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Noribogaine (12-hydroxyibogamine): a biologically active metabolite of the antiaddictive drug ibogaine.
    Baumann MH; Pablo JP; Ali SF; Rothman RB; Mash DC
    Ann N Y Acad Sci; 2000 Sep; 914():354-68. PubMed ID: 11085335
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterization of multiple sites of action of ibogaine.
    Sershen H; Hashim A; Lajtha A
    Alkaloids Chem Biol; 2001; 56():115-33. PubMed ID: 11705104
    [No Abstract]   [Full Text] [Related]  

  • 44. Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents.
    Kuehne ME; He L; Jokiel PA; Pace CJ; Fleck MW; Maisonneuve IM; Glick SD; Bidlack JM
    J Med Chem; 2003 Jun; 46(13):2716-30. PubMed ID: 12801235
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaine.
    Staley JK; Ouyang Q; Pablo J; Hearn WL; Flynn DD; Rothman RB; Rice KC; Mash DC
    Psychopharmacology (Berl); 1996 Sep; 127(1):10-8. PubMed ID: 8880938
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nicotinic receptor-mediated enhancement of long-term potentiation involves activation of metabotropic glutamate receptors and ryanodine-sensitive calcium stores in the dentate gyrus.
    Welsby P; Rowan M; Anwyl R
    Eur J Neurosci; 2006 Dec; 24(11):3109-18. PubMed ID: 17156372
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antinociceptive and toxic effects of (+)-epibatidine oxalate attributable to nicotinic agonist activity.
    Rupniak NM; Patel S; Marwood R; Webb J; Traynor JR; Elliott J; Freedman SB; Fletcher SR; Hill RG
    Br J Pharmacol; 1994 Dec; 113(4):1487-93. PubMed ID: 7889306
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacogenetic variability in neuronal nicotinic receptor-mediated antinociception.
    Flores CM; Wilson SG; Mogil JS
    Pharmacogenetics; 1999 Oct; 9(5):619-25. PubMed ID: 10591542
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Blockade of nicotinic receptor-mediated release of dopamine from striatal synaptosomes by chlorisondamine and other nicotinic antagonists administered in vitro.
    el-Bizri H; Clarke PB
    Br J Pharmacol; 1994 Feb; 111(2):406-13. PubMed ID: 8004384
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Alkaloids indolizidine 235B', quinolizidine 1-epi-207I, and the tricyclic 205B are potent and selective noncompetitive inhibitors of nicotinic acetylcholine receptors.
    Tsuneki H; You Y; Toyooka N; Kagawa S; Kobayashi S; Sasaoka T; Nemoto H; Kimura I; Dani JA
    Mol Pharmacol; 2004 Oct; 66(4):1061-9. PubMed ID: 15258256
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ibogaine, a noncompetitive inhibitor of serotonin transport, acts by stabilizing the cytoplasm-facing state of the transporter.
    Jacobs MT; Zhang YW; Campbell SD; Rudnick G
    J Biol Chem; 2007 Oct; 282(40):29441-7. PubMed ID: 17698848
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Addiction research. Ibogaine therapy: a 'vast, uncontrolled experiment'.
    Vastag B
    Science; 2005 Apr; 308(5720):345-6. PubMed ID: 15831735
    [No Abstract]   [Full Text] [Related]  

  • 53. Evaluating the toxicity and therapeutic potential of ibogaine in the treatment of chronic opioid abuse.
    Luz M; Mash DC
    Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1019-1022. PubMed ID: 34139922
    [No Abstract]   [Full Text] [Related]  

  • 54. Ibogaine: a review.
    Alper KR
    Alkaloids Chem Biol; 2001; 56():1-38. PubMed ID: 11705103
    [No Abstract]   [Full Text] [Related]  

  • 55. Ibogaine-Mediated ROS/Antioxidant Elevation in Isolated Rat Uterus Is β-Adrenergic Receptors and K
    Tatalović N; Vidonja Uzelac T; Oreščanin Dušić Z; Nikolić-Kokić A; Bresjanac M; Blagojević D
    Antioxidants (Basel); 2021 Nov; 10(11):. PubMed ID: 34829663
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ibogaine produces neurodegeneration in rat, but not mouse, cerebellum. Neurohistological biomarkers of Purkinje cell loss.
    Scallet AC; Ye X; Rountree R; Nony P; Ali SF
    Ann N Y Acad Sci; 1996 Oct; 801():217-26. PubMed ID: 8959036
    [No Abstract]   [Full Text] [Related]  

  • 57. Hallucinogen Persisting Perception Disorder After Ibogaine Treatment for Opioid Dependence.
    Knuijver T; Belgers M; Markus W; Verkes RJ; van Oosteren T; Schellekens A
    J Clin Psychopharmacol; 2018 Dec; 38(6):646-648. PubMed ID: 30300292
    [No Abstract]   [Full Text] [Related]  

  • 58. Response to Luz & Mash on cardiac toxicity of ibogaine.
    Schellekens A; Kramers K; Knuijver T; Belgers M; Donders R; Verkes RJ
    Addiction; 2022 Mar; 117(3):837-838. PubMed ID: 34859515
    [No Abstract]   [Full Text] [Related]  

  • 59. Anxiogenic action of ibogaine.
    Popik P; Wróbel M
    Alkaloids Chem Biol; 2001; 56():227-33. PubMed ID: 11705110
    [No Abstract]   [Full Text] [Related]  

  • 60. Ibogaine and Their Analogs as Therapeutics for Neurological and Psychiatric Disorders.
    Kargbo RB
    ACS Med Chem Lett; 2022 Jun; 13(6):888-890. PubMed ID: 35707155
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.